TLSA
No price yet
Announcements
Nothing here yet
Daily updates
- Tiziana Completes Enrollment and Begins Dosing in Phase 2 Intranasal Foralumab Alzheimer’s TrialOct 16, 2026
- Tiziana Life Sciences filed an FDA application seeking Orphan Drug Designation for intranasal foralumab in multiple system atrophy, a rare neurodegenerative disorder without approved disease-modifying treatments.Sep 30, 2026
- Tiziana Life Sciences entered an MOU to evaluate intranasal foralumab with anti-CD20 therapy in RRMSSep 17, 2026
FDA designations
Nothing here yet
News
- Tiziana completes dosing of the final patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's diseaseOct 16, 2026
- Tiziana Life Sciences doses the first participants in the ALS BANYAN clinical trial of intranasal foralumabSep 28, 2026
- Tiziana announced that the last patient completed the last visit in the Phase 2a INFORM-MS trial of intranasal foralumabSep 21, 2026
- Tiziana Life Sciences signed a memorandum of understanding with King Abdullah International Medical Research CenterSep 17, 2026
- Tiziana reported reduced brain inflammation in the third multiple system atrophy patient treated with intranasal ForalumabJul 31, 2026